Literature DB >> 10884065

Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.

D Braida1, M Sala.   

Abstract

Cannabinoids which impair rat working memory appear to inhibit hippocampal extracellular acetylcholine (Ach) release and reduce choline uptake through an interaction with CB1 cannabinoid receptors. Here we report that CP 55,940, a potent bicyclic synthetic cannabinoid analog, dose-dependently impaired rat performance, when given i.p. 20 min before an eight-arm radial maze test. The selective CB1 cannabinoid receptor antagonist SR 141716A, given i.p. 20 min earlier, significantly reduced the memory deficit Pretreatment with eptastigmine, a second generation cholinesterase inhibitor, given orally 100 min before the cannabinoid agonist, relieved the memory impairment without affecting CP 55,940-induced behavioural alterations such as reduced spontaneous motor activity, analgesia and hind limb splaying. These data suggest that cannabinoid-induced working memory impairment is mediated through a central cholinergic blockade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884065     DOI: 10.1097/00001756-200006260-00044

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  16 in total

Review 1.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

2.  Cannabinoid and cholinergic systems interact during performance of a short-term memory task in the rat.

Authors:  Anushka V Goonawardena; Lianne Robinson; Robert E Hampson; Gernot Riedel
Journal:  Learn Mem       Date:  2010-09-28       Impact factor: 2.460

Review 3.  Cognitive function as an emerging treatment target for marijuana addiction.

Authors:  Mehmet Sofuoglu; Dawn E Sugarman; Kathleen M Carroll
Journal:  Exp Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.157

Review 4.  Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?

Authors:  Nadia Solowij; Patricia T Michie
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

5.  Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.

Authors:  M Kathmann; B Weber; A Zimmer; E Schlicker
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation.

Authors:  José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

7.  Pharmacological effects of cannabinoids on the reference and working memory functions in mice.

Authors:  Avdesh Avdesh; Yikai Hoe; Ralph N Martins; Mathew T Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

8.  Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Authors:  E L Theunissen; P Heckman; E B de Sousa Fernandes Perna; K P C Kuypers; A Sambeth; A Blokland; J Prickaerts; S W Toennes; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2014-07-08       Impact factor: 4.530

9.  Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.

Authors:  Daniela Braida; Valeria Capurro; Alessia Zani; Tiziana Rubino; Daniela Viganò; Daniela Parolaro; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

Review 10.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.